AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

Journal of Experimental Medicine

Volumn 205, Issue 11, 2008, Pages 2657-2671

  Zhou, Liang L ^a   Zhao, Yun ^a   Ringrose, Ashley ^a   Degeer, Donna ^a   Kennah, Erin ^a   Lin, Ann E J ^a   Sheng, Guoqing ^b,c   Li, Xiao Jiang ^b   Turhan, Ali ^d   Jiang, Xiaoyan ^a,e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d UNIVERSITÉ DE POITIERS   (France)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; JANUS KINASE 2; STAT5 PROTEIN; AHI1 PROTEIN, MOUSE; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PRIMER DNA; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AHI1 ONCOGENE; ANIMAL CELL; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL GROWTH; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOPRECIPITATION; METABOLISM; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPRECIPITATION; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PHOSPHORYLATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 58149156479     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20072316     Document Type: Article

References (50)

1. Goldman, J.M., and J.V. Melo. 2003. Chronic myeloid leukemia- advances in biology and new approaches to treatment. N. Engl. J. Med. 349:1451-1464.
2. Jiang, X., C. Smith, A. Eaves, and C. Eaves. 2007. The challenges of targeting chronic myeloid leukemia stem cells. Clin. Lymph. Myeloma. 7:S71-S80.
3. Lugo, T.G., A.M. Pendergast, A.J. Muller, and O.N. Witte. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1079-1082.
4. Druker, B.J., S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, and N.B. Lydon. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566.
5. Sattler, M., and J.D. Griffin. 2003. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin. Hematol. 40:4-10.
6. Jiang, X. 2007. Molecular and cellular mechanisms of deregulated he- matopoietic stem cell functions in chronic myeloid leukemia. In Cancer Nanotechnology. American Scientific Publishers. pp. 135-157.
7. Druker, B.J., M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-1037.
8. Kantarjian, H., C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, et al. 2002. Hematologic and cytogenetic responses to ima- tinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346: 645-652.
9. O'Brien, S.G., F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J.J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New. Eng. J. Med. 348:994-1004.
10. Deininger, M., E. Buchdunger, and B.J. Druker. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 105:2640-2653.
11. O'Hare, T., A.S. Corbin, and B.J. Druker. 2006. Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 16:92-99.
12. Azam, M., R.R. Latek, and G.Q. Daley. 2003. Mechanisms of auto- inhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:831-843.
13. Shah, N.P., J.M. Nicoll, B. Nagar, M.E. Gorre, R.L. Paquette, J. Kuriyan, and C.L. Sawyers. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117-125.
14. Shah, N.P., C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305:399-401.
15. Weisberg, E., P.W. Manley, W. Breitenstein, J. Bruggen, S.W. Cowan- Jacob, A. Ray, B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 7:129-141.
16. Graham, S.M., H.G. J orgensen, E. Allan, C. Pearson, M.J. Alcorn, L. Richmond, and T.L. Holyoake. 2002. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 99:319-325.
17. Copland, M., A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M. Barow, J.C. Mountford, and T.L. Holyoake. 2006. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood. 107:4532-4539.
18. Jiang, X., Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves, and C. Eaves. 2007. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 21:926-935.
19. Jiang, X., K.M. Saw, A. Eaves, and C. Eaves. 2007. Instability of BCR- ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl. Cancer Inst. 99:680-693.
20. Jiang, X., Z. Hanna, M. Kaouass, L. Girard, and P. J olicoeur. 2002. Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. J. Virol. 76:9046-9059.
21. Girard, L., Z. Hanna, N. Beaulieu, C.D. Hoemann, C. Simard, C.A. Kozak, and P. J olicoeur. 1996. Frequent provirus insertional muta- genesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 10:1930-1944.
22. + human leukemias of AHI-1, a gene activated by insertional muta- genesis in mouse models of leukemia. Blood. 103:3897-3904.
23. Ringrose, A., Y. Zhou, E. Pang, L. Zhou, A.E. Lin, G. Sheng, X.J. Li, A. Weng, M.W. Su, M.R. Pittelkow, and X. Jiang. 2006. Evidence for an oncogenic role of AHI-1 in Sezary Syndrome, a leukemic variant of human cutaneous T-cell lymphomas. Leukemia. 20:1593-1601.
24. Jamieson, C.H., L.E. Ailles, S.J. Dylla, M. Muijtjens, C. Jones, J.L. Zehnder, J. Gotlib, K. Li, M.G. Manz, A. Keating, et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351:657-667.
25. Chalandon, Y., X. Jiang, G. Hazelwood, S. Loutet, E. Conneally, A. Eaves, and C. Eaves. 2002. Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage reprogram- ming. Blood. 99:3197-3204.
26. Dugray, A., J.F. Geay, A. Foudi, M.L. Bonnet, W. Vainchenker, F. Wendling, F. Louache, and A.G. Turhan. 2001. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette. Leukemia. 15:1658-1662.
27. Era, T., and O.N. Witte. 2000. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Natl. Acad. Sci. USA. 97:1737-1742.
28. Elefanty, A.G., and S. Cory. 1992. bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro. Blood.79:1271-1281.
29. Borzillo, G.V., R.A. Ashmun, and C.J. Sherr. 1990. Macrophage lineage switching of murine early pre-B lymphoid cells expressing transduced fms genes. Mol. Cell. Biol. 10:2703-2714.
30. Chalandon, Y., X. Jiang, S. Loutet, A.C. Eaves, and C.J. Eaves. 2004. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR- ABL. Leukemia. 18:1006-1012.
31. Baker, S.J., S.G. Rane, and E.P. Reddy. 2007. Hematopoietic cytokine receptor signaling. Oncogene. 26:6724-6737.
32. Steelman, L.S., S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand, and J.A. McCubrey. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18:189-218.
33. Chang, J.M., D. Metcalf, R.A. Lang, T.J. Gonda, and G.R. J ohnson. 1989. Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression. Blood. 73:1487-1497.
34. Just, U., M. Katsuno, C. Stocking, E. Spooncer, and M. Dexter. 1993. Targeted in vivo infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads to immortalization and leukemic transformation of primitive hematopoietic progenitor cells. Growth Factors. 9:41-55.
35. Wilson-Rawls, J., J. Liu, P. Laneuville, and R.B. Arlinghaus. 1997. P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and consti- tutively activates Jak2. Leukemia. 11:428-431.
36. Jiang, X., A. Lopez, T. Holyoake, A. Eaves, and C. Eaves. 1999. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA. 96:12804-12809.
37. Teglund, S., C. McKay, E. Schuetz, J.M. van Deursen, D. Stravopodis,D. Wang, M. Brown, S. Bodner, G. Grosveld, and J.N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:841-850.
38. Wang, Y., D. Cai, C. Brendel, C. Barett, P. Erben, P.W. Manley, A. Hochhaus, A. Neubauer, and A. Burchert. 2007. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/ STAT-5 pathway activation. Blood. 109:2147-2155.
39. Scherr, M., A. Chaturvedi, K. Battmer, I. Dallmann, B. Schultheis, A. Ganser, and M. Eder. 2006. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood. 107:3279-3287.
40. Miyamoto, N., K. Sugita, K. Goi, T. Inukai, K. Lijima, T. Tezuka, S. Kojika, M. Nakamura, K. Kagami, and S. Nakazawa. 2001. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia. 15:1758-1768.
41. Xie, S., Y. Wang, J. Liu, T. Sun, M.B. Wilson, T.E. Smithgall, and R.B. Arlinghaus. 2001. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 20:6188-6195.
42. Samanta, A.K., H. Lin, T. Sun, H. Kantarjian, and R.B. Arlinghaus. 2006. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66:6468-6472.
43. Van Etten, R.A. 2002. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene. 21:8643-8651.
44. Seet, B.T., I. Dikic, M.M. Zhou, and T. Pawson. 2006. Reading protein modifications with interaction domains. Nat. Rev. Mol. Cell Biol. 7:473-483.
45. Dai, Z., and A.-M. Pendergast. 1995. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9:2569-2582.
46. Jiang, X., E. Ng, C. Yip, W. Eisterer, Y. Chalandon, M. Stuible, A. Eaves, and C.J. Eaves. 2002. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood. 100:3731-3740.
47. Dull, T., R. Zufferey, M. Kelly, R.J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471.
48. Kinsella, T.M., and G.P. Nolan. 1996. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 7:1405-1413.
49. Eaves, C.J. 1995. Assays of hemopoietic progenitor cells. In Williams Hematology. E. Beutler, M.A. Lichtman, B.S. Coller, and T.J.Kipps,editors. McGraw-Hill, Inc. L22-L26.
50. Harlow, E., and D. Lane. 1988. Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.